DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20212246

Case series of mucormycosis occurring in patients of COVID-19

Drashti J. Patel, Paras G. Patel, Purvi P. Patel, BrijeshKumar Sapariya, Moxa B. Parmar, Nehal S. Diwanji

Abstract


Mucormycosis is an umbrella term used for diseases caused by many non-septate filamentous fungal species which is caused by sub-phylum Mucormycotina. It is an acute opportunistic and aggressive fulminant invasive infection that can occur in immunocompromised patients, such as uncontrolled diabetes, renal failure, organ transplant, long-term corticosteroid and immunosuppressive therapy, AIDS, malignancy and corona virus disease 2019 (COVID 19) infections. Mucormycosis is now third most common invasive mycoses after candidiasis and aspergillosis. The COVID-19 infection is characterised by wide range of disease patterns, ranging from mild to life-threatening pneumonia. Many bacterial and fungal co-infections may exist and may be associated with preexisting morbidity or may develop as a hospital-acquired infection such as ventilator-associated pneumonia. Extensive use of corticosteroids and broad-spectrum antibiotics lead to exacerbation of preexisting disease. The aim of this study is to identify the risk factors along with high index of suspicion, early diagnosis and aggressive management of mucormycosis.


Keywords


Mucormycosis, Diabetes, COVID-19, Fungal infections, Nasal cavity

Full Text:

PDF

References


Alinaghi S, Afsahi AM, Pour M, Behnezhad F, Salehi MA, Barzegary A, et al. Late Complications of COVID-19; a Systematic Review of Current Evidence. Arch Acad Emerg Med. 2021;9(1):e14.

Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;1-6.

Prakash, H.; Chakrabarti, A. Epidemiology of Mucormycosis in India. Microorganisms. 2021;9: 523.

Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073-81.

Auluck A. Maxillary necrosis by mucormycosis. A case report and literature review. Med Oral Patol Oral Cir Bucal. 2007;12:360-4.

Petrikkos G, Skiada A, Patel J, Roilides E, Thomas J. Walsh, Dimitrios P. Kontoyiannis. Epidemiology and Clinical Manifestations of Mucormycosis, Clinical Infectious Diseases. 2012;54:S23-34

Prenissl J, Jaacks LM, Mohan V. Variation in health system performance for managing diabetes among states in India: a cross-sectional study of individuals aged 15 to 49 years. BMC Med. 2019;17:92.

Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19 a meta-analysis. JAMA. 2020;324(13):1330-41.

Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care. 2003;30:593-605.

Orlandi M, Lepri G, Bruni C, Wang Y, Bartoloni A, Zammarchi L, et al. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clinical Rheumatology. 2020;39(7), 2043-7.

Kumar G, Adams A, Hererra M, Rojas ER, Singh V, Sakhuja A, et al. Predictors and outcomes of hais in COVID-19 patients. Int J Infect Dis. 2020;104(3):287-92.

Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, et al. IL-6 inhibition in critically Ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne) 2020;7:583897.

Soman R, Sunavala A. Post COVID-19 Mucormycosis - from the Frying Pan into the Fire. Journal of the association of Physicians of India. 2021;69:13-14.

Goel A, Kini U, Shetty S. Role of histopathology as an aid to prognosis in rhino-orbito-cerebral zygomycosis. Indian J Pathol Microbiol. 2010;53:253-7.